HSCS (HeartSciences) Price-to-Funds-From-Operations: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSCS HeartSciences Inc HSCS
18 GF Score
Price $3.99
GF Value $0.54
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is HeartSciences Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

HSCS
18GF Score
HeartSciences Inc HSCS
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $3.99 is trading 638.9% above its estimated GF Value™ of $0.54. GuruFocus considers HeartSciences to be Significantly Overvalued.

Key valuation signals for HSCS:

  • Price-to-Funds-From-Operations:
  • GF Value™: $0.54 vs. price of $3.99 (638.9% above fair value)
  • GF Score™: 18/100 with 10 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HeartSciences Business Description

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
18GF Score

Get the complete analysis for HSCS

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.99
Price
$0.54
GF Value